Securities Code: 002693
Securities Abbreviation: Shuangcheng Pharmaceutical
Announcement No.: 2026-046
Hainan Shuangcheng Pharmaceutical Co., Ltd.
Announcement on Signing a License Agreement
The Company and the entire Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Special Reminders:
-
Drug R&D is characterized by long cycles, high investment, and high risk, with the risk that R&D project progress and R&D results may not meet expectations.
-
The milestone payments stipulated in the agreement are subject to certain conditions. If the Company fails to complete the corresponding matters at the agreed milestone points, the counterparty has the right to unilaterally terminate the agreement. Upon termination of the agreement, all payments corresponding to the milestone points shall be refunded in full. Therefore, whether this cooperation can achieve the agreed milestone payments is uncertain. Investors are advised to make cautious decisions and be aware of investment risks.
-
In accordance with the relevant provisions of the "Shenzhen Stock Exchange Stock Listing Rules," "Measures for the Administration of Information Disclosure Exemption for Listed Companies," and other laws and regulations, as well as the confidentiality requirements of the counterparty, the name of the counterparty and the product project name in this transaction constitute trade secrets and commercially sensitive information. Disclosure or fulfillment of relevant obligations may lead to unfair competition and harm the interests of the Company and investors. The Company has completed the internal information disclosure exemption procedures and has exempted the disclosure of information about the counterparty and the specific details of the agreement. Investors are advised to be aware of the risks.
I. Overview of Agreement Signing